132 related articles for article (PubMed ID: 36931171)
21. Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4
Ghods A; Mehdipour F; Shariat M; Talei AR; Ghaderi A
Mol Immunol; 2021 Sep; 137():52-56. PubMed ID: 34214829
[TBL] [Abstract][Full Text] [Related]
22. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
23. In situ localization of tumor cells associated with the epithelial-mesenchymal transition marker Snail and the prognostic impact of lymphocytes in the tumor microenvironment in invasive ductal breast cancer.
Alkatout I; Hübner F; Wenners A; Hedderich J; Wiedermann M; Sánchez C; Röcken C; Mathiak M; Maass N; Klapper W
Exp Mol Pathol; 2017 Apr; 102(2):268-275. PubMed ID: 28232080
[TBL] [Abstract][Full Text] [Related]
24. IL-33 in the tumor microenvironment is associated with the accumulation of FoxP3-positive regulatory T cells in human esophageal carcinomas.
Cui G; Li Z; Ren J; Yuan A
Virchows Arch; 2019 Nov; 475(5):579-586. PubMed ID: 31062086
[TBL] [Abstract][Full Text] [Related]
25. Tumoral FOXP3 has potential oncogenic function in conjunction with the p53 tumor suppressor protein and infiltrated Tregs in human breast carcinomas.
Won KY; Kim HS; Sung JY; Kim GY; Lee J; Park YK; Kim YW; Suh JH; Lim SJ
Pathol Res Pract; 2013 Dec; 209(12):767-73. PubMed ID: 24071443
[TBL] [Abstract][Full Text] [Related]
26. FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis.
Sambucci M; Gargano F; De Rosa V; De Bardi M; Picozza M; Placido R; Ruggieri S; Capone A; Gasperini C; Matarese G; Battistini L; Borsellino G
Sci Rep; 2018 Feb; 8(1):3674. PubMed ID: 29487369
[TBL] [Abstract][Full Text] [Related]
27. Alternative Splicing of
Joly AL; Seitz C; Liu S; Kuznetsov NV; Gertow K; Westerberg LS; Paulsson-Berne G; Hansson GK; Andersson J
Circ Res; 2018 May; 122(10):1385-1394. PubMed ID: 29618596
[TBL] [Abstract][Full Text] [Related]
28. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis.
Shou J; Zhang Z; Lai Y; Chen Z; Huang J
BMC Cancer; 2016 Aug; 16(1):687. PubMed ID: 27566250
[TBL] [Abstract][Full Text] [Related]
29. Peritumoral FOXP3⁺ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3⁺ regulatory T cell is prognostic predictor of breast cancer patients.
Liu F; Li Y; Ren M; Zhang X; Guo X; Lang R; Gu F; Fu L
Breast Cancer Res Treat; 2012 Sep; 135(2):459-67. PubMed ID: 22842982
[TBL] [Abstract][Full Text] [Related]
30. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S
BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744
[TBL] [Abstract][Full Text] [Related]
31. PRMT5 Associates With the FOXP3 Homomer and When Disabled Enhances Targeted p185
Nagai Y; Ji MQ; Zhu F; Xiao Y; Tanaka Y; Kambayashi T; Fujimoto S; Goldberg MM; Zhang H; Li B; Ohtani T; Greene MI
Front Immunol; 2019; 10():174. PubMed ID: 30800128
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of FOXP3 expression in triple-negative breast cancer.
Lee S; Cho EY; Park YH; Ahn JS; Im YH
Acta Oncol; 2013 Jan; 52(1):73-81. PubMed ID: 23075422
[TBL] [Abstract][Full Text] [Related]
33. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer.
Zhuo C; Xu Y; Ying M; Li Q; Huang L; Li D; Cai S; Li B
Immunol Res; 2015 Mar; 61(3):338-47. PubMed ID: 25608795
[TBL] [Abstract][Full Text] [Related]
34. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
[TBL] [Abstract][Full Text] [Related]
35. Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis.
Yu J; Sun J; Wang SE; Li H; Cao S; Cong Y; Liu J; Ren X
Clin Dev Immunol; 2011; 2011():469135. PubMed ID: 22110525
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
[TBL] [Abstract][Full Text] [Related]
37. The Role of FOXP3 in Human Cancers.
Szylberg Ł; Karbownik D; Marszałek A
Anticancer Res; 2016 Aug; 36(8):3789-94. PubMed ID: 27466478
[TBL] [Abstract][Full Text] [Related]
38. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
39. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
Stenström J; Hedenfalk I; Hagerling C
Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
[TBL] [Abstract][Full Text] [Related]
40. Accumulation of FoxP3+ T regulatory cells in the tumor microenvironment of human colorectal adenomas.
Hua W; Yuan A; Zheng W; Li C; Cui J; Pang Z; Zhang L; Li Z; Goll R; Cui G
Pathol Res Pract; 2016 Feb; 212(2):106-12. PubMed ID: 26724144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]